Oramed Pharmaceuticals Inc

This management proposal seeks shareholder approval to increase the share reserve under the Company’s 2019 Long-Term Incentive Plan by 3,000,000 shares, raising the total authorized for awards to 12,500,000 shares. Management frames the amendment as essential for maintaining competitive long-term equity incentives to attract, retain and motivate employees, consultants and non-employee directors, and the Compensation Committee cites the flexibility needed to grant options, RSUs, PSUs and other awards. The filing discloses the Plan’s history of previous increases (initially 1,000,000, later increased to 3,000,000, then to 7,500,000, then to 9,500,000) and that, as of the record date, approximately 958,245 shares remained available—highlighting existing run-rate and potential burn-rate concerns for investors. The Plan contains typical anti-dilution and recycling provisions (forfeited, cancelled or expired awards may be added back), caps on annual awards to any grantee, and administrator discretion over award terms; ISOs are subject to separate limitations. The amendment requires a shareholder vote under Nasdaq rules because it materially increases the aggregate number of shares available for issuance. From a governance perspective, shareholders should weigh the benefits of management’s ability to grant long-term incentives against dilution and overhang: large recent equity grants to executives (as disclosed elsewhere in the proxy) may raise concerns about executive compensation levels and issuance pace. The Board argues the amendment aligns management and stockholders through multi-year vesting and performance-based awards, but the filed materials also disclose wide discretion for the administrator to determine vesting and performance metrics, which can both target performance and raise monitoring needs. Potential vote dynamics include broker non-votes (this proposal is non-routine) and stockholder sensitivity to dilution; if stockholders approve, the Company gains capacity to continue sizable equity grants that could impact future GAAP expense and share count. Overall, the proposal is a standard equity-plan increase with customary safeguards and caveats; investors should evaluate it in the context of recent grant activity, current available share pool, and the Company’s hiring and retention needs versus prospective dilution.

This non-binding advisory proposal asks stockholders to approve the compensation paid to the named executive officers as disclosed in the proxy, including base salaries, discretionary bonuses, and significant equity awards (RSUs and PSUs). Management argues the program balances a fixed salary component with long-term equity incentives designed to align executives’ interests with long-term shareholder value; the Compensation Committee notes benchmarking and discretionary review. The proxy provides detailed pay tables, disclosure of substantial equity grants in 2024–2025, and a Pay Versus Performance table, which together allow investors to assess realized compensation relative to Company performance—though the complexity of equity valuation (ASC 718 accounting, PSUs tied to market/performance conditions) can obscure short-term cash impact. Because the vote is advisory, a negative outcome would not be binding but would obligate the Board and Compensation Committee to consider stockholder concerns when setting future pay. The filing states the Company intends to hold this advisory vote biennially but is seeking shareholder input on frequency in a separate proposal; the Board notes prior frequency outcomes influenced this cadence. Investors should weigh whether equity-heavy compensation, vesting schedules, and performance conditions appropriately incentivize long-term value creation versus creating potential for outsized dilution or misaligned short-term incentives. Given the magnitude of recent equity awards to executives disclosed elsewhere in the proxy, some investors may scrutinize the size and structure of those awards even if they support long-term incentive alignment. The Board recommends a vote FOR; any material dissent would likely prompt engagement and potential adjustments to compensation design.

This advisory proposal asks shareholders to choose the preferred frequency—one, two, or three years—for non-binding say-on-pay votes. Management recommends every three years, arguing that the Company’s equity compensation is structured for multi-year vesting and performance horizons, so a triennial review better matches incentive timelines and gives the Board and Compensation Committee time to implement changes in response to shareholder feedback. The filing references prior advisory votes and that Dodd-Frank/SEC rules require at least one such frequency vote every six years, explaining why this is being presented now. From a governance perspective, more frequent votes (annually) provide more regular accountability but can create short-term focus; less frequent votes (every three years) reduce administrative burden and allow long-term policies to take effect before reassessment. The vote is non-binding; the Board will consider the outcome but is not required to adopt it. Institutional investors often prefer annual votes for accountability; hedge funds and governance-focused investors sometimes push for more frequent engagement. Shareholders should consider the tradeoff between ongoing oversight and allowing sufficient time to evaluate long-term compensation outcomes when expressing their preference.

The Adjournment Proposal requests shareholder authorization allowing the Board’s designated proxies to adjourn or postpone the Annual Meeting to a later date to enable additional solicitation of votes if any of the substantive proposals lack sufficient support at the scheduled meeting. Management’s rationale is procedural: it provides the Company flexibility to continue outreach and avoid an immediate defeat of proposals that may be curable with further solicitation, particularly given broker non-votes on non-routine matters. The proposal is routine in practice and commonly approved; it does not change substantive corporate governance or rights but can delay finality for stockholders until adjourned sessions conclude. Voting to approve this measure protects the Company’s ability to secure needed majorities without reconvening a new meeting, thereby conserving resources. Potential investor concerns are limited but can include desire for timely resolution; approval could result in postponement that delays implementation of approved items or further prolongs uncertainty. The Board recommends a vote FOR; brokers are permitted to vote on this routine procedural item if beneficial owners do not provide instructions. In contested or controversial situations, adjournments may be used strategically to obtain additional votes, so shareholders should be aware of the practical effects of granting this authority.